Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319980 | 0.98 | CPB2 (0.53) | CPB2CA2CA1LMNAZDHHC7 | |
| SCHEMBL277442 | 0.98 | CPB2 (0.53) | CPB2CA2CA1LMNAZDHHC7 | |
| Ammonia Solution, Strong SCHEMBL5121318 | 0.96 | CPB2 (0.51) | CPB2CA2CA1LMNAZDHHC7 | |
| Methyl Alcohol SCHEMBL7668985 | 0.96 | CPB2 (0.51) | CPB2CA2CA1LMNAZDHHC7 | |
| SCHEMBL3176263 | 0.94 | CA2 (0.52) | CPB2CA2CA1SLC1A2SLC1A1 | |
| Acetic Acid SCHEMBL3260364 | 0.93 | CPB2 (0.49) | CPB2CA2CA1LMNAZDHHC7 | |
| Ethyl Acetate SCHEMBL1279632 | 0.91 | CPB2 (0.47) | CPB2CA2CA1LMNAZDHHC7 | |
| Ethyl Acetate SCHEMBL5064725 | 0.91 | CPB2 (0.47) | CPB2CA2CA1LMNAZDHHC7 | |
| Ethyl Acetate SCHEMBL17005456 | 0.88 | CPB2 (0.45) | CPB2CA2LMNAZDHHC7GRIK1 | |
| Ethyl Acetate SCHEMBL17699277 | 0.88 | CPB2 (0.45) | CPB2CA2LMNAZDHHC7GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1311488-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002014285-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| CN-1243507-A | Bis-sulfonamide hydroxamic acids as MMP inhibitors | UPJOHN CO (US) | 2000-02-02 | — | — | CN | disclosed |
| EP-0973733-A1 | BIS-SULFONOMIDES HYDROXAMIC ACIDS AS MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5859061-A | MATRIX METALLOPROTEINASE INHIBITORS; TREATING DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION | PHARMACIA & UPJOHN COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998031664-A1 | BIS-SULFONOMIDES HYDROXAMIC ACIDS AS MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
| US-5716973-A | ADMINISTERING DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5559140-A | VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0565631-B1 | ANTI-VIRAL COMPOUNDS | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | disclosed |
| EP-0565631-A1 | ANTI-VIRAL COMPOUNDS. | MERRELL DOW PHARMA (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992012123-A1 | ANTI-VIRAL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
| US-4833136-A | ANTIINFLAMMATORY AGENTS | BEECHAM GROUP P.L.C. (GB) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CA2 4181/4885CA1 4605/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CA2 4178/4885CA1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.